SH0322

SH0322 is a next-generation adeno-associated virus (AAV) gene therapy being developed by StrongHolt Therapeutics for the treatment of Duchenne muscular dystrophy (DMD). The therapy utilizes a myotropic capsid and a novel muscle-specific promoter to deliver a miniaturized utrophin transgene. Utrophin is a structural paralog of dystrophin; its overexpression is intended to compensate for the deficiency of functional dystrophin in DMD patients. This approach offers a potential safety advantage by leveraging central immunological tolerance to utrophin, potentially reducing the risk of immune responses compared to dystrophin-based therapies. Preclinical studies in mdx mice have demonstrated that SH0322 can improve muscle histology, reduce biomarkers of muscle injury, and enhance physical performance, supporting its advancement toward clinical trials.

Other names

next-generation AAV-utrophin gene therapy